Stacks

The 2026 bibliometric and evidence-based review (PMC13068985) confirms that tirzepatide — a dual GIP/GLP-1 receptor agonist — produces MASH resolution in 44–62% of participants across dose arms versus 10% placebo, with fibrosis-stage improvement in 55–62% versus 30% placebo. Its dual incretin mechanism distinguishes it from single-agonist comparators in protocol design.

A 2026 critical analysis published in Pharmaceuticals (MDPI) maps two competing off-target profiles for semaglutide: a context-dependent oncogenic signal concentrated in thyroid C-cells and pancreatic tissue, and a robust cardioprotective mechanism that attenuates chemotherapy-induced and ischemia-driven cardiac injury via GLP-1 receptor–mediated PI3K/AKT and NF-κB suppression. Protocol designers must account for both vectors simultaneously.

Based on preclinical data available through 2026, BPC-157 and TB-500 drive tendon and ligament repair through mechanistically distinct angiogenic pathways — neither compound has been validated in a controlled human trial. BPC-157 operates via FAK-paxillin and VEGFR2 signalling at the injury site; TB-500 acts systemically through G-actin sequestration and endothelial progenitor cell recruitment. No head-to-head RCT exists.

No direct co-administration trial for semaglutide and thymosin alpha-1 (Tα1) exists as of 2026. The interaction map is built from each compound's independent pharmacology: semaglutide's GLP-1R–mediated anti-inflammatory signaling and Tα1's TLR-dependent immune priming operate through non-overlapping receptor systems, making a direct pharmacodynamic collision unlikely but formally uncharacterised.